ImmunityBio, Inc. - Common Stock (NQ:IBRX)

Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗

Today 3:53 EST

Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume.

IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug ↗

Topics ETFs Economy Government

Today 2:08 EST

Traders are closely watching positioning, as short interest hit a record 13.7% of the free float amid a jump in retail activity on Stocktwits this week.

Topics Government

Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs ↗

February 02, 2026

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire...

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

February 19, 2026

Via Finterra

Topics Lawsuit

ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗

February 19, 2026

The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

February 19, 2026

Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗

February 19, 2026

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

The standoff ended when the EU granted conditional approval, sending shares up 42% on Wednesday.

Topics ETFs Economy Government

Why IBRX Stock Became A High-Stakes Showdown Between Shorts And Retail Bulls ↗

February 18, 2026

Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer ↗

February 18, 2026

On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal scrutiny.

Via The Motley Fool

Topics Initial Public Offering Stocks

Here are the top movers in Wednesday's session. ↗

February 18, 2026

Via Chartmill

Why ImmunityBio Stock Is Soaring Today ↗

February 18, 2026

The biopharma outfit's flagship cancer-fighting drug continues to rack up approvals.

Via The Motley Fool

Discover the most active stocks in Wednesday's session. ↗

February 18, 2026

Via Chartmill

Top movers in Wednesday's session ↗

February 18, 2026

Via Chartmill

IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally ↗

February 18, 2026

The European Commission granted conditional marketing authorization to ImmunityBio’s Anktiva, implying that it wants more data from the company.

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

February 18, 2026

How High Can IBRX Stock Go Now? Here’s What Wall Street Thinks After Saudi Nod For Bladder Cancer Filing ↗

February 18, 2026

Koyfin data shows an average 12-month target of $11.8, implying a 96% upside from the stock's current levels.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

February 17, 2026

From Pomerantz LLP

Via GlobeNewswire

IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗

February 17, 2026

The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks.

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

February 17, 2026

Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗

February 17, 2026

Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade.

Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗

Topics Artificial Intelligence ETFs Economy

February 17, 2026

The comments come as ImmunityBio pushes for broader global access to Anktiva across indications.

IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU ↗

February 13, 2026

Retail investors are now looking forward to a full approval of Anktiva in the EU for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.

ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC)

February 10, 2026

Via AB Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

February 02, 2026

From ImmunityBio

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗

January 26, 2026

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

Via The Motley Fool

Topics Stocks

IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research ↗

January 26, 2026

Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.

Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗

Topics Death ETFs

January 26, 2026